Results from MTN-041 (the MAMMA study) were published in JIAS.

Results from MTN-041 (the MAMMA study) were published in JIAS. The MAMMA study explored community attitudes and perceptions about the use of two HIV prevention products – Truvada as daily oral PrEP and the monthly dapivirine vaginal ring – during pregnancy and breastfeeding. The study took place in Malawi, South Africa, Uganda and Zimbabwe, and involved group discussions with pregnant and breastfeeding women, as well as their male partners, mothers and mothers-in-law. The study team also conducted interviews with community leaders, health care providers, midwives and traditional birth attendants, among others. Study results indicated that pregnant and breastfeeding women welcome options for HIV prevention that recognize personal preference and autonomy. These findings – and others from the study – are helping to inform the implementation of the DELIVER (MTN-042) and B-PROTECTED (MTN-043) studies in pregnant women and breastfeeding women, respectively.